JW Pharmaceutical Corporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 842.27 million compared to KRW 610.01 million a year ago. Net loss was KRW 17,910.8 million compared to net income of KRW 8,290.97 million a year ago. Basic loss per share from continuing operations was KRW 727.451 compared to basic earnings per share from continuing operations of KRW 333.3333 a year ago. Basic loss per share was KRW 727.451 compared to basic earnings per share of KRW 333.3333 a year ago.
For the nine months, sales was KRW 2,693.4 million compared to KRW 3,006.73 million a year ago. Net income was KRW 12,041.57 million compared to KRW 18,857.23 million a year ago. Basic earnings per share from continuing operations was KRW 489.2157 compared to KRW 754.902 a year ago. Basic earnings per share was KRW 489.2157 compared to KRW 754.902 a year ago.